Advertisement

Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature

Abstract

Gefitinib is the current first-line treatment for advanced lung adenocarcinoma with epidermal growth factor receptor (EGFR) gene mutations. The possibility of using gefitinib as neoadjuvant therapy is interesting because of the low toxicity profile of tyrosine kinase inhibitors. Here we report the case of a 67-year-old nonsmoking woman affected by locally advanced lung adenocarcinoma, in whom one-year treatment with gefitinib rendered the tumor amenable to surgical removal. The results of ongoing clinical trials exploring the ability of preoperative gefitinib to achieve better results than can be obtained with chemotherapy in patients selected on the basis of EGFR mutations are urgently awaited.

Tumori 2013; 99(5): e241 - e244

Article Type: CASE REPORT

DOI:10.1700/1377.15324

Authors

Ilaria Marech, Angelo Vacca, Antonio Gnoni, Nicola Silvestris, Vito Lorusso

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Marech, Ilaria [PubMed] [Google Scholar]
    National Cancer Center – Istituto Tumori Giovanni Paolo II, IRCCS, Bari, Italy
  • Vacca, Angelo [PubMed] [Google Scholar]
    Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy
  • Gnoni, Antonio [PubMed] [Google Scholar]
    Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy
  • Silvestris, Nicola [PubMed] [Google Scholar]
    National Cancer Center – Istituto Tumori Giovanni Paolo II, IRCCS, Bari, Italy
  • Lorusso, Vito [PubMed] [Google Scholar]
    National Cancer Center – Istituto Tumori Giovanni Paolo II, IRCCS, Bari, Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.